Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.37 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16708451 | 0.83 | SMN1; SMN2 (0.44) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD | |
| SCHEMBL19055337 | 0.80 | SMN1; SMN2 (0.42) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD | |
| SCHEMBL19055367 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD | |
| SCHEMBL6637109 | 0.78 | AKR1B1 (0.43) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD | |
| SCHEMBL19098941 | 0.77 | SMN1; SMN2 (0.40) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD | |
| SCHEMBL19055368 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1HTTHPGDOPRK1 | |
| 1,2-Dichlorobenzene SCHEMBL28140034 | 0.73 | LMNA (0.42) | ALDH1A1POLBADRB1ADRB2L3MBTL1 | |
| SCHEMBL18371908 | 0.73 | SMN1; SMN2 (0.36) | SMN1; SMN2AKR1B1ALDH1A1HPGDOPRK1 | |
| SCHEMBL2426412 | 0.72 | AKR1B1 (0.43) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD | |
| SCHEMBL15083012 | 0.72 | AKR1B1 (0.43) | SMN1; SMN2AKR1B1ALDH1A1HTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1647279-A2 | Inhibition of apoptosis using interleukin-1beta-converting enzyme (ICE)/CED-3 family inhibitors | Idun Pharmaceuticals, Inc. (US) | 2006-04-19 | — | — | EP | disclosed |
| EP-0929311-B8 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS INC (US) | 2006-02-01 | — | — | EP | disclosed |
| EP-1443935-A2 | TREATMENT OF INFECTIOUS DISEASE USING INTERLEUKIN-1 BETA CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | Idun Pharmaceuticals, Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040058850-A1 | Using caspase inhibitor; antiinflammatory agents | IDUN PHARMACEUTICALS, INC. | 2004-03-25 | — | — | US | disclosed |
| US-6693096-B2 | SUPPRESSING PROTEASE ACTIVITY | IDUN PHARMACEUTICALS, INC. | 2004-02-17 | — | — | US | disclosed |
| US-20030186842-A1 | Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family | IDUN PHARMACEUTICALS, INC. (US) | 2003-10-02 | — | — | US | disclosed |
| US-6610683-B2 | Programmed cell death; expansion of hematopoietic cells, for prolonging viability of an organ for transplantation, and maintaining viability of cell lines used in bioproduction | IDUN PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2003-06-26 | — | — | US | disclosed |
| WO-2003032918-A2 | TREATMENT OF INFECTIOUS DISEASE USING INTERLEUKIN-1 BETA CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 2003-04-24 | — | — | WO | disclosed |
| US-6531467-B2 | Inhibition of inflammation using interleukin-1β-converting enzyme (ICE)/CED-3 family inhibitors | IDUN PHARMACEUTICALS, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20010044415-A1 | Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors | FRITZ LAWRENCE C (US) | 2001-11-22 | — | — | US | disclosed |
| EP-0929311-A4 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS INC (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6200969-B1 | CONTACTING CELLS WITH REAGENT WHICH SUPPRESSES PROTEASE ACTIVITY OF INTERLEUKIN-1.BETA.-CONVERTING ENZYME (ICE)/CED-3 FAMILY, INHIBITING APOPTOSIS IN CELL POPULATION TO EXPANDING OR INCREASING SURVIVAL OF CELL POPULATION | IDUN PHARMACEUTICALS, INC. | 2001-03-13 | — | — | US | disclosed |
| US-6184244-B1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | IDUN PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| WO-2001000658-A1 | C-TERMINAL MODIFIED (N-SUBSTITUTED)-2-INDOLYLCARBONYLDIPEPTIDES AS INHIBITORS OF THE ICE/CED-3 FAMILY OF CYSTEINE PROTEASES | IDUN PHARMACEUTICALS, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| CN-1234038-A | C-terminally modified (N-substituted) -2-indolyl dipeptides as inhibitors of ICE/ced-3 class of cysteine proteases | IDUN PHARMACEUTICALS INC (US) | 1999-11-03 | — | — | CN | disclosed |
| EP-0929311-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1 beta-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | Idun Pharmaceuticals, Inc. (US) | 1999-07-21 | — | — | EP | disclosed |
| US-5877197-A | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases | CONATUS PHARMACEUTICALS, INC. | 1999-03-02 | — | — | US | disclosed |
| US-5869519-A | USE OF SUCH COMPOSITIONS IN THE TREATMENT OF PATIENTS SUFFERING INFLAMMATORY, AUTOIMMUNE AND NEURODEGENERATIVE DISEASES, FOR THE PREVENTION OF ISCHEMIC INJURY, AND FOR THE PRESERVATION OF ORGANS THAT ARE TO UNDERGO A TRANSPLANTATION | IDUN PHARMACEUTICALS, INC. (US) | 1999-02-09 | — | — | US | disclosed |
| WO-1998010778-A1 | INHIBITION OF APOPTOSIS USING INTERLEUKIN-1β-CONVERTING ENZYME (ICE)/CED-3 FAMILY INHIBITORS | IDUN PHARMACEUTICALS, INC. (US) | 1998-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186842-A1 | Contacting a cell population with an inhibiting effective amount of a reagent that suppresses the protease activity of at least one member of the interleukin-1beta- converting enzyme (ICE)/CED-3 family | CASP1, SERPINB1, IL1B | SMN1; SMN2 3084/4885AKR1B1 2099/4885ALDH1A1 1947/4885 |
| US-20030119748-A1 | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ice/ced-3 family of cysteine proteases | CASP3, CASP1, IAPP | SMN1; SMN2 2573/4885AKR1B1 4607/4885ALDH1A1 4494/4885 |
| US-20040058850-A1 | Using caspase inhibitor; antiinflammatory agents | CASP1, PYCARD, CASP3 | SMN1; SMN2 3113/4885AKR1B1 1850/4885ALDH1A1 1942/4885 |
| US-20010044415-A1 | Inhibition of apoptosis using interleukin-1B-converting enzyme (ICE)/CED-3 family inhibitors | CASP1, IL1B, APAF1 | SMN1; SMN2 2550/4885AKR1B1 924/4885ALDH1A1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.